This is extremely intriguing. Thank you. Upon first
This is extremely intriguing. Thank you. Upon first thought, yes, pdl-1 might in fact move LL beyond oncology, HIV? Anti-PD-1s/AntiPDL-1s? Dostarlimab? Keytruda? Does ViiV/GSK or Merck know this given their deeply entrenched positions in both HIV and Cancer? Really? They had better. Otherwise, if you stumbled upon this and so did the company, then they really need to be educated on what they own. I see a patent extension from MERCK if this is true. 10 of Billion$
Yes creativ micro can measure this. Is inflammation implied in this theory?
I had to read this post 10+ times to think about the implications. WTF, My69z?
How did you stumble upon this? (Links please)
I came across LL in January 2014 searching for a cure for HIV through CCR5 blockage post-Timothy Brown (not necessarily gp120 or CXCR4 blockage) but this is ALSO including CXCR4 phenotypes??
I read it yet again…so this is turning “cold” T cells “HOT”. Has such a thing ever been described? We have cold tumors turning hot with the “priming” of LL (how, not, if is the question that plagues me) and now T-cells can turn “hot” from “cold”?
My head is spinning.
Immediate questions in my head: How or can this be applied to HIV Cure and what implications could this possibly have either HIV reservoirs?
WTF, man.
Great work! Really. My hat is off to you. I hope this is true. If you have links or sources, please post them.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Russel Metals Inc. Reports Third Quarter Results for 2025 Russel Metals Inc. (TSX:RUS) has recently shared its financial performance for the three-month period ending September 30, 2025. The results reflect a positive trajectory in revenue and strategic initiatives to enhance its market position. Key Financial Metrics Overview In this quarter, Russel Metals has...
Continue Reading
KBC Group's Capital Position Remains Strong KBC Group has reported a robust standing in its capital levels, significantly exceeding the minimum capital requirements mandated by the European Central Bank (ECB). As part of the Supervisory Review and Evaluation Process (SREP) scheduled for the upcoming year, KBC received formal notification regarding its capital metrics....
Continue Reading
Synlogic Provides Third Quarter 2024 Financial Results Synlogic, Inc. (NASDAQ: SYBX), a prominent biopharmaceutical firm dedicated to developing innovative therapeutics for serious diseases, has recently outlined its financial performance for the third quarter of 2024. The organization is actively working on advancing its mission to enhance healthcare through...
Continue Reading
Incannex Healthcare's Remarkable Financial Progress Incannex Healthcare Inc. (NASDAQ: IXHL) is making impressive strides in the biopharmaceutical world, focusing on breakthrough treatments for chronic diseases. Their recent fiscal year report outlines not only financial outcomes but also a plethora of operational and clinical advancements aimed at addressing significant...
Continue Reading
Alpha Liquid Terminal Introduces ChatAnalyst Financial Agent Recently, a game-changing tool was launched that promises to redefine how individuals manage and interpret financial data. This is powered by the innovative company, Alpha Liquid Terminal. The newly unveiled AI-driven financial analyst agent, known as ChatAnalyst, is designed to simplify and streamline financial...
Continue Reading